Skip To The Main Content
Parenteral Drug Association Connecting People, Science and Regulation ®

Press Releases

  • 10/09/2020

    PDA Announces 2020 Drug Delivery Innovation Award Winners

    Bethesda, Md., – The Parenteral Drug Association (PDA) announced the winners of the 2020 PDA Drug Delivery Innovation Awards at the 2020 PDA Universe of Pre-Filled Syringes and Injection Devices, Oct. 5-8, a virtual event. Awardees were recognized for their technical innovations in advancing the field of bio/pharmaceutical delivery devices.
  • 08/25/2020

    PDA and BioPhorum Consortium Complete Work on PUPSIT Research and Points to Consider

    Bethesda, Md., – The Parenteral Drug Association (PDA) and BioPhorum today announced that the Sterile Filtration Quality Risk Management (SFQRM), jointly created by the two organizations, has completed its final publication to help clarify industry thinking on the implications of pre-use post-sterilization integrity testing (PUPSIT) of sterilizing filters. The work product includes two research papers and two points-to-consider technical documents.
  • 08/04/2020

    PDA Confirms U.S. FDA’s Douglas Throckmorton as an Opening Plenary Speaker for Virtual 2020 PDA/FDA Joint Regulatory Conference

    Bethesda, Md. – The Parenteral Drug Association (PDA) today announced that it has confirmed Douglas Throckmorton, MD, Deputy Director for Regulatory Programs, Center for Drug Evaluation and Research (CDER), U.S. FDA, as an opening plenary speaker of the 2020 PDA/FDA Joint Regulatory Conference, which will be held virtually Sept. 14 – 16.
  • 07/23/2020

    BSR/PDA Standard 02-201x Cryopreservation Standard Available for Public Comment

    Bethesda, Md. – The Parenteral Drug Association (PDA) today announced the availability of BSR/PDA Standard 02-201x, Cryopreservation of Cells for Use in Cell Therapies and Regenerative Medicine Manufacturing for public comment. To receive a copy of this draft standard, email PDA at [email protected] The public comments period concludes September 7, 2020 EDT. There is no charge for the draft standard.
  • 06/01/2020

    PDA Launches New Website for the PDA Foundation, a 501(c)(3) Organization Site includes a donation section for companies to underwrite certain PDA activities

    Bethesda, Md. – The Parenteral Drug Association (PDA) today announced the availability of a new website for the PDA Foundation, a 501(c)(3) nonprofit founded in 1997 to help support PDA and other industry activities. This new website makes it easier for industry stakeholders to donate money for various activities, as it includes an online processing system.
  • 04/23/2020

    PDA Forms Coronavirus Pandemic Response Task Force, New Advanced Therapy Advisory Board

    Bethesda, Md. – The Parenteral Drug Association, Inc. (PDA) today announced two new volunteer opportunities and changes to its Board of Directors/Executive Committee following its spring Board of Directors meeting.
  • 04/17/2020

    PDA Announces Availability of ANSI/PDA Standard 001-2020 on Purchasing Controls

    Bethesda, Md. – The Parenteral Drug Association (PDA) today announced the availability of ANSI/PDA Standard 001-2020, Enhanced Purchasing Controls to Support the Bio-Pharmaceutical, Pharmaceutical, Medical Devices, and Combination Products Industries, which was approved by the ANSI Board of Standards Review on March 13, 2020.
  • 04/07/2020

    Parenteral Drug Association Announces its 2020 – 2026 Strategic Plan

    Bethesda, Md. – The Parenteral Drug Association, Inc. (PDA) today announced the availability of its 2020 – 2026 Strategic Plan, which was developed to assist PDA in achieving its vision to be the premier global leader in advancing bio/pharmaceutical manufacturing, science, technology, and regulation to enable members to better serve patients. The plan was developed by PDA’s Strategic Planning Committee at the direction of the PDA Board of Directors.
  • 03/27/2020

    Parenteral Drug Association Announces Measures to Support Pharma/Biopharma Industries during Covid-19 Pandemic

    Bethesda, Md. – The Parenteral Drug Association (PDA) announced that it is suspending membership expirations retroactively to March 1 and continuing until the end of June. All members will continue to enjoy the benefits of membership, even if you are unable to pay due to the impact of the corona virus pandemic.
  • 03/10/2020

    PDA Names Former Eli Lilly Exec. Glenn E. Wright Vice President of Scientific and Regulatory Affairs Dr. Tina Morris is leaving PDA to become Executive Director at AAPS

    Bethesda, Md. – The Parenteral Drug Association (PDA) today announced the appointment of former Eli Lilly and Co. - Executive Glenn E. Wright as Vice President of Scientific and Regulatory Affairs, effective March 23. Mr. Wright most recently worked as Senior Director of Quality Operations at Exelead, a contract manufacturer. Mr. Wright also has worked for Amgen and Pfizer.
  • 02/12/2020

    PDA Europe Parenteral Packaging to Address EU MDR 117 and Closed Systems

    Berlin – Parenteral Drug Association Europe (PDA EU) is hosting its 10th Parenteral Packaging Conference in Basel, Switzerland, 25-26 February. The conference features presentations and discussions by industry leaders and technical experts from pharma and supplier companies. This year’s event includes expert discussions on the EU’s Medical Device Regulation 117 and on closed system transfer devices.
  • 02/05/2020

    PDA and AAMI Announce Plans to Explore Collaborations

    Bethesda, Md. – The Parenteral Drug Association (PDA) and the Association for the Advancement of Medical Instrumentation (AAMI) today announced their agreement to explore collaborations to further the missions of both organizations and enhance value to their members, stakeholders, and their respective communities at large. The two heads of each organization met at PDA’s headquarters on Jan. 29 to sign a collaboration agreement.
  • 01/28/2020

    PDA Announces 2020 United States Conference Schedule

    Bethesda, Md. – The Parenteral Drug Association (PDA) today announced its schedule of U.S. conferences for the year. The busy schedule includes PDA’s signature events and new “hot topic” workshops.
  • 12/17/2019

    PDA Europe Releases 2020 Conference Schedule

    Berlin – The Parenteral Drug Association (PDA) Europe today announced its 2020 events calendar, which includes nine conferences throughout the EU. These events are developed by all-volunteer subject-matter experts who work with PDA staff to help educate pharmaceutical professionals on important topics related to biopharmaceuticals, manufacturing science, and regulatory affairs.
  • 12/17/2019

    PDA and IPEC Federation Publish Technical Report No. 54-6 Formalized Risk Assessment for Excipients

    Bethesda, Md., / Brussels, Belgium – The Parenteral Drug Association (PDA) and the International Pharmaceutical Excipients Council Federation (IPEC) as an outcome of its collaboration established in March 2018, today announce the joint publication of a Technical Report for Formalized Risk Assessment for Excipients.
  • 12/09/2019

    PDA Announces Election Results for 2020 Board of Directors; Jette Christensen Assumes Role as Chair, 2020-2021

    Bethesda, Md. – The Parenteral Drug Association (PDA) today announced the results of its Board of Directors Election for the term beginning January 1, 2020. Each year, PDA’s global membership votes to select new directors for the nonprofit Association’s all volunteer Board of Directors, and the Board appoints one Director. In odd years, the membership elects new volunteer officers, who serve two-year terms (except for the chair elect, who serves for six years as chair-elect, chair, and, finally, as immediate-past-chair).
  • 12/04/2019

    PDA GMP for APIs Education Webinar Now an "ICH Recognised Training Programme"

    Bethesda, Md. – The Parenteral Drug Association (PDA) is proud to announce that its “ICH Q7 GMP for APIs” online training module is now endorsed by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use as an “ICH Recognised Training Programme.”
  • 11/05/2019

    U.S. FDA’s CDER Director Janet Woodcock and Johns Hopkins Researcher Thomas Stanton to Headline 2019 PDA Quality Week

    Bethesda, Md., – The Parenteral Drug Association (PDA) today announced the participation of U.S. FDA Center for Drug Evaluation and Research Director (CDER), Janet Woodcock, MD, and Johns Hopkins University researcher and author, Thomas Stanton, MA/JD, as keynote speakers for the 2019 PDA Risk Management in the Regulatory Landscape Conference, at the Capital Hilton, Washington, DC, Dec. 9–10. The conference is the first of three during PDA’s first “Quality Week.”
  • 10/29/2019

    PDA Announces First Drug Delivery Innovation Award Winners at 2019 Universe of Pre-Filled Syringes and Injection Devices Conference

    Bethesda, Md. – The Parenteral Drug Association (PDA) announced FujiFilm Kyowa Kirin Biologics, Co., Ltd. has won PDA’s new Drug Delivery Innovation Award and Congruence Medical Solutions and Santen Pharmaceuticals have won PDA’s Partnership in Drug Delivery Innovation Award. The Drug Delivery Awards were introduced in 2019 to recognize technical innovation advancing the field of bio/pharmaceutical manufacturing.
  • 10/08/2019

    ISPE and PDA Publish Guide to Improving Quality Culture in Pharmaceutical Industry

    Bethesda, Md. – The Parenteral Drug Association (PDA) and the International Society for Pharmaceutical Engineering (ISPE) today announce the joint publication of a guide for Root Cause Analysis (RCA) to help the pharmaceutical industry improve quality culture by providing recommendations for tools, techniques, and processes.
123456789